Merkel Cell Carcinoma

Merkel carcinoma is very rare skin cancer, with high mortality. The standard treatment until 2017 was surgery, radiotherapy, and chemotherapy. Since 2017 FDA and EC approved Avelumab for the marketing and sale, based in phase II clinical trial. In Argentina was approved registration for the treatment of patients with metastatic Merkel cell carcinoma, controversies in authorizations, leads to delay in the start of treatment, and sometimes requires the intervention of the justice.